Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Alessandra Carobbio, BSc, Elisa Rumi, MD, Valerio De Stefano, MD, Lara Mannelli, MD, Francesco Mannelli, MD, Giada Rotunno, PhD, Giacomo Coltro, MD, Silvia Betti, MD PhD, Chiara Cavalloni, MD, Maria Chiara Finazzi, MD, Juergen Thiele, MD PhD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD, Tiziano Barbui, MD

Blood (2019) 134 (Supplement_1): 1657.

https://doi.org/10.1182/blood-2019-124302

Published: 2019

Journal Articles

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Hans Michael Kvasnicka, Gina Liviana Frank, Marlene Lemp, Fabian Lang, MD, Juergen Thiele, MD

Blood (2017) 130 (Supplement 1): 2913.

https://doi.org/10.1182/blood.V130.Suppl_1.2913.2913

Published: 2017

Journal Articles

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Martin Schalling, Bettina Gisslinger, Roland Jäger, PhD, Edith Bogner, Ashot S Harutyunyan, PhD, Jelena D Milosevic Feenstra, Nicole C.C. Them, Maria-Theresa Krauth, MD, Leonhard Muellauer, MD, Juergen Thiele, MD PhD, Robert Kralovics

Blood (2016) 128 (22): 1931.

https://doi.org/10.1182/blood.V128.22.1931.1931

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Tiziano Barbui, MD, Alessandro M. Vannucchi, Veronika Buxhofer-Ausch, Valerio De Stefano, MD, Silvia Betti, MD, Alessandro Rambaldi, Elisa Rumi, MD, Marco Ruggeri, MD, Francesco Rodighiero, Maria Luigia Randi, Irene Bertozzi, Heinz Gisslinger, MD, Guido Finazzi, MD, Alessandra Carobbio, Juergen Thiele, MD, Francesco Passamonti, MD, Chiara Falcone, Ayalew Tefferi, MD

Blood (2015) 126 (23): 4055.

https://doi.org/10.1182/blood.V126.23.4055.4055

Published: 2015

Journal Articles

Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria

Georg Jeryczynski, MD, Juergen Thiele, MD, Bettina Gisslinger, Maria Theresa Krauth, MD, Martin Schalling, MSc, Ana-Iris Schiefer, MD, Ingrid Simonitsch-Klupp, MD, Leonhard Muellauer, MD, Heinz Gisslinger, MD

Blood (2015) 126 (23): 2816.

https://doi.org/10.1182/blood.V126.23.2816.2816

Published: 2015

Journal Articles

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Heinz Gisslinger, MD, Juergen Thiele, MD PhD, Bettina Gisslinger, MSc, Tiina Berg, B.Sc., Martin Schalling, M.Sc., Ashot S Harutyunyan, MD, Jelena D. Milosevic, M.Sc., Klaudia Bagienski, M.Sc., Nicole C.C. Them, M.Sc., Veronika Buxhofer-Ausch, Guenther Nirnberger, Leonhard Muellauer, MD, Robert Kralovics, PhD

Blood (2014) 124 (21): 3167.

https://doi.org/10.1182/blood.V124.21.3167.3167

Published: 2014

Journal Articles

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3182.

https://doi.org/10.1182/blood.V124.21.3182.3182

Published: 2014

Journal Articles

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Hans Michael Kvasnicka, MD, PhD, Juergen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4056.

https://doi.org/10.1182/blood.V122.21.4056.4056

Published: 2013

Journal Articles

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Nicolaus Kröger, MD, Haefaa Alchalby, MD, Tatjana Zabelina, MD, Hans-Michael Kvasnicka, MD, Juergen Thiele, MD, PhD, Guntram Büsche, MD, Hans Kreipe, MD

Blood (2013) 122 (21): 2078.

https://doi.org/10.1182/blood.V122.21.2078.2078

Published: 2013

Journal Articles

Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Blood (2007) 110 (11): 683.

https://doi.org/10.1182/blood.V110.11.683.683

Published: 2007

Journal Articles

Rapid Regression of Bone Marrow Fibrosis after Dose-Reduced Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.

Nicolaus Kroeger, MD, Juergen Thiele, MD, Axel Zander, MD, Michael Kvasnicka, MD

Blood (2006) 108 (11): 374.

https://doi.org/10.1182/blood.V108.11.374.374

Published: 2006

Journal Articles

Acute Panmyelosis with Myelofibrosis: An Evaluation of Distinctive Clinicopathological Features Including Bone Marrow Stroma.

Annette Schmitt-Graeff, MD, Juergen Thiele, MD, Hans M. Kvasnicka, MD, Michael Lübbert, MD

Blood (2005) 106 (11): 4568.

https://doi.org/10.1182/blood.V106.11.4568.4568

Published: 2005

Journal Articles

Visualization of c-Mpl Expression in Ph-Negative Myeloproliferative Diseases and So-Called Essential Thrombocythemia with Ringed Sideroblasts by Confocal Laser Scanning Microscopy.

Annette Schmitt-Graeff, MD, Juergen Thiele, MD, Hans M. Kvasnicka, MD, Ulrich Germing, MD, Michael Luebbert, MD, Cornelius Waller, MD, Sabine Haxelmanns, Roland Nitschke, Ph.D, Heike L. Pahl, Ph.D, Jerry L. Spivak, MD, Ph.D.

Blood (2004) 104 (11): 2440.

https://doi.org/10.1182/blood.V104.11.2440.2440

Published: 2004

Journal Articles

Neutrophil PRV-1 mRNA Overexpression in Chronic Idiopathic Myelofibrosis May Be Associated with Poor Prognosis.

Heinz Gisslinger, MD, Steffen Klippel, PD, Hermann Heimpel, MD, Mathias Kees, MD, Alexandra Kaider, PD, Juergen Thiele, MD, Heike L. Pahl, PD

Blood (2004) 104 (11): 4762.

https://doi.org/10.1182/blood.V104.11.4762.4762

Published: 2004

NARROW

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Validation of the International Prognostic Score for Thrombosis in Essential Thrombocythemia (IPSET) in Patients with Pre-Fibrotic Primary Myelofibrosis

Heterogeneity of Bone Marrow Morphology in Patients with Polycythemia Vera Resistant to First and Second Line Therapies - Impact of Hydroxyurea Dosage on MDS-like Progression

Impact of High Molecular Risk Mutations on Overall Survival in WHO-Defined Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Practice-Relevant Revision of Ipset-Thrombosis Based on 1019 Patients with WHO-Defined Essential Thrombocythemia

Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria

Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential Thrombocythemia

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

The Kinetic Of Bone Marrow Fibrosis Regression Predicts Outcome In Myelofibrosis Patients After Allogeneic SCT

Dose-Reduced Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis. Results from a Multicenter Prospective Trial of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Rapid Regression of Bone Marrow Fibrosis after Dose-Reduced Allogeneic Stem Cell Transplantation in Patients with Myelofibrosis.

Acute Panmyelosis with Myelofibrosis: An Evaluation of Distinctive Clinicopathological Features Including Bone Marrow Stroma.

Visualization of c-Mpl Expression in Ph-Negative Myeloproliferative Diseases and So-Called Essential Thrombocythemia with Ringed Sideroblasts by Confocal Laser Scanning Microscopy.

Neutrophil PRV-1 mRNA Overexpression in Chronic Idiopathic Myelofibrosis May Be Associated with Poor Prognosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only